利奈唑胺在不同疾病患者中药动学变化的临床意义  

Clinical significance of pharmacokinetics changes of linezolid in patients with different diseases

作　　者：董海燕[1] 董亚琳[1] 杨华[1] 刘娟娟[1] 

机构地区：[1]西安交通大学医学院第一附属医院药学部,陕西西安710061

出　　处：《中国新药与临床杂志》2010年第3期170-174,共5页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：利奈唑胺是第一个用于临床的新型噁唑烷酮类抗菌药,在体内外对葡萄球菌、链球菌、肠球菌等多重耐药革兰阳性细菌有强大的抗菌作用,可作为治疗革兰阳性菌感染的糖肽类多重耐药的替换药物。现对其在囊性纤维化患者、肾功能不全患者、中性粒细胞减少的癌症患者、血液滤过患者等不同疾病患者中的药动学特点进行综述,以期为其在国内的临床合理应用提供参考。Linezolid is the first oxazolidinone antibiotic and has been currently marketed in China. At present, linezolid can be used as an alternative drug to glycopeptides in treatment of multidrug-resistant Grampositive bacteria infections including methicillin-resistant Staphylococcus aureus （ MRSA）,Staphylococcus epidermidis, and vancomycin-resistant Enterococcus faecium and Enterococcus faecalis. In this paper, different pharmacokinetics profiles of linezolid in patients with cystic fibrosis, renal failure, neutropenia in cancer, and hemofiltration, etc, are reviewed to provide more information about rationally clinical application of linezolid in China.

关 键 词：利奈唑胺 药动学 葡萄球菌 金黄色 耐甲氧西林 临床方案 

分 类 号：R978.1[医药卫生—药品]